Navigation Links
Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
Date:4/15/2008

- Bavituximab Causes Pro-Inflammatory Effects in the Tumor Microenvironment

That May Contribute to Its Anti-Tumor Efficacy -

- Studies Show Similar Results for a New Fully Human Version of the

Antibody -

SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that preclinical studies being presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) confirm a unique mechanism by which bavituximab, its lead anti-phosphatidylserine (anti-PS) antibody in Phase II cancer trials, affects the tumor microenvironment and contributes to its anti-tumor efficacy. The research, which was conducted by scientists at Peregrine, showed similar effects for bavituximab and for PGN635, a fully human version of the bavituximab antibody.

In the in vitro and in vivo studies, lead author Dr. Monica Friedrich and colleagues at Peregrine show that both bavituximab and PGN635 cause the destruction of targeted cells. They demonstrate that by blocking the anti-inflammatory signals of the phosphatidylserine found on the surface of targeted cells, these anti-PS antibodies could create a unique tumor microenvironment, by enhancing production of the pro-inflammatory cytokines TNF-alpha and GM-CSF, while decreasing production of anti-inflammatory cytokines such as interleukin 10. The studies also show that bavituximab and PGN635 promote the migration of tumor-killing macrophages and induce antibody-dependent cell-mediated cytotoxicity. In addition, the studies showed that similar to bavituximab, PGN635 localizes to tumors but not to healthy tissue.

"The AACR Annual Meeting represents an ideal oppor
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
3. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
4. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
8. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
9. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
10. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
11. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
(Date:11/26/2014)... DIEGO , Nov. 25, 2014 Halozyme Therapeutics, ... the Piper Jaffray Healthcare Conference in New York ... EDT/10:00 a.m. PDT . Dr. Helen Torley , ... The presentation will be webcast through the "Investors" ... a recording will be made available for 90 days following ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Delcath Systems, Inc. (Nasdaq: DCTH ) ... Senior Vice President of Medical Device Research and Development ... to the position of Vice President of Pharmaceutical Research ... based in the Company,s Queensbury, New York facility and ...
... Thomson Reuters, a global provider of information ... version of its award-winning Clinical Xpert Navigator ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO) ... to access complete patient clinical data — ...
Cached Medicine Technology:Delcath Strengthens Research and Development Team with Key Appointments 2Delcath Strengthens Research and Development Team with Key Appointments 3Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3
(Date:11/26/2014)... 26, 2014 GI for Life announced ... reductions in prices of their popular nutritional supplements: ... D3 . Discounts of 40% will be offered ... for Life’s proprietary ColoVite supplement is a scientifically formulated ... colon health. One easy-to-take colon vitamin with ALL the ...
(Date:11/26/2014)... Arlington, VA (PRWEB) November 26, 2014 ... foster greater effectiveness in containing and stopping Ebola, ... long-term stability in healthcare systems in West Africa. ... Care Systems to Stop Ebola: Anthropologists Offer Insights,” ... held by the American Anthropological Association (AAA), Fri., ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 For those with ... new LES MILLS BODYPUMP™ classes at the University ... the workout they've been looking for. The 45- 60 minute ... Anschutz Health and Wellness Center fitness club memberships. , LES ... workouts are fast-paced and are aimed at fast results ...
(Date:11/26/2014)... November 26, 2014 One of the ... at some point in her life is choosing the ... excellent platform for ladies to purchase high quality outfits. ... bridesmaid dresses. People now can pick their suitable bridesmaid ... chic dresses always make ladies look scintillating and highlight ...
(Date:11/26/2014)... number of emergency department visits in the United States rose ... million in 2011, according to the U.S. Centers for Disease ... people were going to ERs with non-urgent medical needs: 96 ... two hours of arriving at the ER. In 2010, that ... percent of patients arrived at the ER after normal business ...
Breaking Medicine News(10 mins):Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Royal Blue Bridesmaid Dresses Now Are Available for Christmas at BellasDress.com 2Health News:ER Visits on the Rise, Study Reports 2
... which could presumably play a major role in the development// ... down after examination of tumor tissue from 53 breast cancer ... which confirmed the findings. This new discovery could provide ... haunting women. ,Our improved understanding of cancer biology and genetic ...
... Japan Thursday announced a grant of $7 million for ... grant assistance would enable the Sardar Vallavbhai Patel Postgraduate ... facilities and effectively contribute towards dispensation of healthcare to ... embassy. , ,Notes concerning the project were signed ...
... doses of vitamins and minerals// are allowing themselves to ... researchers. , ,No one knows what adverse long ... the levels promoted by some alternative therapists and celebrities, ... middle-class professionals who turned to vitamins and minerals in ...
... elderly population may not be checked regularly for chronic ... in them. ,Researchers from Tufts-New England Medical Center, ... of the American Society of Nephrology that there remained ... for the geriatric patients with this health condition., ...
... on hopes for a new drug to treat women with //low ... more studies to be done on the Intrinsa patch made by ... effects the drug may induce, the Los Angeles Times reported. , ... to restore healthy sexual appetites to women struggling with low desire., ...
... attempted to commit suicide repeatedly can now be treated ... found to give better results than the other treatments ... findings were published in the current issue of JAMA. ... conducted a randomized controlled trial to determine whether a ...
Cached Medicine News:Health News:Vitamin Supplements - Good, The Bad And The Ugly 2Health News:Vitamin Supplements - Good, The Bad And The Ugly 3Health News:Geriatric Patients With Chronic Kidney Disease May Not Be Treated Properly 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3Health News:Suicidal Tendencies May Be Treated With Cognitive Therapy 2
... Single Use reloadable linear stapler with ... PI™ disposable stapler is designed for use ... healthy internal tissues. The instrument places a ... when using the 30 VASCULAR cartridges) of ...
... Single Use Loading Units With ... ILA™ 75 (Single Use Reloadable ... ,INDICATIONS The ILA™ 75 single-use ... for use in the resection, ...
... 75 single-use stapler, anastomotic type, is ... transection, and/or the anastomosis of normal, ... ILA™ 75 single-use stapler, anastomotic type, ... resection, transection, and/or the anastomosis of ...
... The PROXIMATE HCS Procedure for Prolapse and ... of titanium staples in 33mm diameter size. ... canal for transection and resection of internal ... surgical treatment of hemorrhoidal disease. The PPH01 ...
Medicine Products: